InfectivologyNews.net

Infectivology Xagena

Clinical effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. A study has assessed the dose-response, safety, and tolerability of single-dose Tafeno ...


Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, follo ...


Between 2000 and 2012 the number of multidrug-resistant ( MDR ) tuberculosis cases in the UK increased from 28 per year to 81 per year. Researchers investigated the proportion of MDR tuberculosis cas ...


ZMapp is an experimental treatment, developed by Mapp Biopharmaceutical, for use with individuals infected with Ebola virus. It has not yet been tested in humans for safety or effectiveness. The pro ...


A prospective cohort study has estimated the prevalence and clinical severity of whooping cough ( pertussis ) in school age children presenting with persistent cough in primary care since the introduc ...


For maximum effect pre-exposure prophylaxis should be targeted to the subpopulations that account for the largest proportion of infections ( population-attributable fraction [ PAF ] ) and for whom the ...


Infections with soil-transmitted helminths ( Ascaris lumbricoides, hookworm, and Trichuris trichiura ) are widespread and often occur concomitantly. These parasitic-worm infections are typically treat ...


The first identified cases of avian influenza A(H7N9) virus infection in humans occurred in China during February and March 2013. Researchers have analyzed data obtained from field investigations to ...


Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to initiate antiretroviral trea ...


The optimum dose of key antiretroviral drugs is often overlooked during product development. The ENCORE1 study compared the efficacy and safety of reduced dose Efavirenz with standard dose Efavirenz i ...


Idenix Pharmaceuticals has announced interim data from the ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral ( DAA ) HCV combination regimen of Samatasvir ...


AbbVie has announced the completion of its phase III clinical program and released results of four additional studies designed to assess investigational all-oral, interferon-free therapy with and with ...


Scarce data are available to assess sexual behaviour of individuals using antiretroviral pre-exposure prophylaxis for HIV prevention. Increased sexual risk taking by individuals using effective HIV pr ...


Respiratory syncytial virus ( RSV ) infection is associated with subsequent recurrent wheeze. Observational studies cannot determine whether RSV infection is the cause of recurrent wheeze or the first ...


Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. Researches have studied the effect of duodenal infusion of donor feces in patients w ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product HyQvia, 100 mg/ml, solution ...


Sovaldi ( Sofosbuvir ) is the first-in-class medicine that provides the first interferon-free treatment option in patients chronic hepatitis C.Hepatitis C virus ( HCV ) infection is a major European p ...


New data from its phase III clinical trial programme, STARTVerso, which is evaluating Faldaprevir in combination with Pegylated Interferon and Ribavirin ( PegIFN/RBV ) were presented at the 64th Annua ...


Gilead Sciences has announced results from two phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue Sofosbuvir plus Ribavirin ( RBV ) for both ...


The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline Bedaquiline ( TMC207; ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati